Athira Pharma Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 67

Employees

  • Stock Symbol
  • ATHA

Stock Symbol

  • Share Price
  • $0.47
  • (As of Friday Closing)

Athira Pharma General Information

Description

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Contact Information

Website
www.athira.com
Formerly Known As
M3 Biotechnology, M3 Biotechnology, Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 18706 North Creek Parkway
  • Suite 104
  • Bothell, WA 98011
  • United States
+1 (425)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 18706 North Creek Parkway
  • Suite 104
  • Bothell, WA 98011
  • United States
+1 (425)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Athira Pharma Stock Performance

As of 14-Feb-2025, Athira Pharma’s stock price is $0.47. Its current market cap is $18.1M with 38.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.47 $0.44 $0.41 - $4.30 $18.1M 38.7M 281K -$2.84

Athira Pharma Financials Summary

As of 30-Sep-2024, Athira Pharma has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (73,218) (78,803) (99,055) 252,897
Revenue 0 0 0 0
EBITDA (108,250) (116,703) (94,794) (54,374)
Net Income (109,222) (117,672) (95,639) (54,853)
Total Assets 86,246 160,245 258,153 332,008
Total Debt 1,314 1,585 1,911 1,920
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Athira Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Athira Pharma‘s full profile, request access.

Request a free trial

Athira Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Athira Pharma‘s full profile, request access.

Request a free trial

Athira Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to
Drug Discovery
Bothell, WA
67 As of 2023

Austin, TX
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Athira Pharma Competitors (15)

One of Athira Pharma’s 15 competitors is Cassava Sciences, a Formerly VC-backed company based in Austin, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cassava Sciences Formerly VC-backed Austin, TX
Quince Therapeutics Formerly VC-backed South San Francisco, CA
Cognition Therapeutics Formerly VC-backed New York, NY
Alzheon Venture Capital-Backed Framingham, MA
Pharmatrophix Venture Capital-Backed Menlo Park, CA
You’re viewing 5 of 15 competitors. Get the full list »

Athira Pharma Patents

Athira Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023263997-A1 Methods of treating neuroinflammatory conditions Pending 04-May-2022
AU-2023265053-A1 Methods of treating neuropathies. Pending 04-May-2022
EP-4482510-A1 Methods of treating covid-related disorders Pending 23-Feb-2022
CA-3240896-A1 Uses of bicyclic compounds for the treatment of diseases Pending 17-Dec-2021
EP-4448100-A1 Uses of bicyclic compounds for the treatment of diseases Pending 17-Dec-2021 A61K31/519
To view Athira Pharma’s complete patent history, request access »

Athira Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Athira Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Athira Pharma‘s full profile, request access.

Request a free trial

Athira Pharma ESG

Risk Overview

Risk Rating

Updated October, 01, 2023

25.56 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,842

Rank

Percentile

Pharmaceuticals

Industry

of 898

Rank

Percentile

Biotechnology

Subindustry

of 402

Rank

Percentile

To view Athira Pharma’s complete esg history, request access »

Athira Pharma FAQs

  • When was Athira Pharma founded?

    Athira Pharma was founded in 2011.

  • Where is Athira Pharma headquartered?

    Athira Pharma is headquartered in Bothell, WA.

  • What is the size of Athira Pharma?

    Athira Pharma has 67 total employees.

  • What industry is Athira Pharma in?

    Athira Pharma’s primary industry is Drug Discovery.

  • Is Athira Pharma a private or public company?

    Athira Pharma is a Public company.

  • What is Athira Pharma’s stock symbol?

    The ticker symbol for Athira Pharma is ATHA.

  • What is the current stock price of Athira Pharma?

    As of 14-Feb-2025 the stock price of Athira Pharma is $0.47.

  • What is the current market cap of Athira Pharma?

    The current market capitalization of Athira Pharma is $18.1M.

  • Who are Athira Pharma’s competitors?

    Cassava Sciences, Quince Therapeutics, Cognition Therapeutics, Alzheon, and Pharmatrophix are some of the 15 competitors of Athira Pharma.

  • What is Athira Pharma’s annual earnings per share (EPS)?

    Athira Pharma’s EPS for 12 months was -$2.84.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »